Answers are grounded in this paper and cite their sources.
Assesses safety and efficacy of 5-FU with panitumumab and sotorasib in frail patients with unresectable cancer, suggesting a new treatment option.
INTRODUCTION: 5-fluorouracil (5-FU) ± targeted therapy is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting. Panitumumab plus sotorasib combination (KRAS G12C inhibitor) are promising in advanced line in KRAS G12C-mutated CRC. Here we assess the safety and efficacy of 5-FU combination with panitumumab and sotorasib as first-line treatment in frail/elderly patients with unresectable KRAS G12C-mutated CRC. METHODS: <50%), and 37 patients will need to be included. PERSPECTIVES: Treatment with 5-FU plus panitumumab and sotorasib could be a promising alternative to 5-FU ± targeted therapy in first-line setting in frail/elderly patients with unresectable KRAS G12C-mutated CRC.
No takes yet. Share an insight, caveat, or question.
Grancher et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: